2006
The Role of Flavin-Containing Monooxygenase (FMO) in the Metabolism of Tamoxifen and Other Tertiary Amines
Krueger S, VanDyke J, Williams D, Hines R. The Role of Flavin-Containing Monooxygenase (FMO) in the Metabolism of Tamoxifen and Other Tertiary Amines. Drug Metabolism Reviews 2006, 38: 139-147. PMID: 16684653, DOI: 10.1080/03602530600569919.Peer-Reviewed Original ResearchConceptsMetabolism of tamoxifenBreast cancer therapyHuman liver microsomesFlavin-Containing MonooxygenaseMetabolic activation pathwayEndometrial cancerTamoxifen metabolismN-oxide productionLiver microsomesTamoxifenMetabolic activationDNA adductionCancer therapyActivation pathwayCytochrome P450Detoxication pathwayN-oxygenationRiskMetabolismLow levelsPathwayChemopreventionNeoplasiaTherapyCancer
2002
GENETIC POLYMORPHISMS OF FLAVIN-CONTAINING MONOOXYGENASE (FMO)
Krueger S, Williams D, Yueh M, Martin S, Hines R, Raucy J, Dolphin C, Shephard E, Phillips I. GENETIC POLYMORPHISMS OF FLAVIN-CONTAINING MONOOXYGENASE (FMO). Drug Metabolism Reviews 2002, 34: 523-532. PMID: 12214664, DOI: 10.1081/dmr-120005653.Peer-Reviewed Original ResearchConceptsFlavin-Containing MonooxygenaseAdult human liverPercent of individualsPlethora of drugsTrimethylamine N-oxygenationDrug metabolismHuman liverGenetic polymorphismsHispanic descentPremature stop codonPolymorphic expressionLungPreliminary evidenceFunctional FMO2African descentXenobiotic toxicityMammalian flavinN-oxygenationFMO2TrimethylaminuriaEthylene thioureaPolymorphismAllelesPatientsExpression